A Phase 1 Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors and Determination of Tumor Receptor Occupancy by U3-1287.

Trial Profile

A Phase 1 Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors and Determination of Tumor Receptor Occupancy by U3-1287.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 19 Dec 2013

At a glance

  • Drugs Patritumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 11 Jun 2013 Planned number of patients changed from 17 to 25 as reported by ClinicalTrials.gov.
    • 01 Mar 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 18 May 2012 Actual initiation date (April 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top